Targeting Bcl-2 for cancer therapy

Zhang, Linlin; Lu, Zaiming; Zhao, Xiangxuan

doi:10.1016/j.bbcan.2021.188569

Cited by 64 publications

(44 citation statements)

References 237 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, advances in genomics and molecular classification provide a lot of biological information that could be of great clinical relevance in the prediction, treatment, and prognosis of this type of tumor in different populations [ 2 , 3 ]. The present results showed that the BCL2 family of proteins balance towards an anti-apoptotic signal related to the higher expression of BCL2 and the increase in the relation BCL2/BAX, as has been previously reported [ 37 , 38 , 39 , 40 , 41 , 42 ]. We hope that our findings can contribute to the improvement inn therapies, survival, and quality of life of patients with this type of tumor.…”

Section: Discussionsupporting

confidence: 89%

Differential Regulation of the EGFR/PI3K/AKT/PTEN Pathway between Low- and High-Grade Gliomas

et al. 2021

View full text Add to dashboard Cite

Gliomas represent 70% of all central system nervous tumors and are classified according to the degree of malignancy as low- or high-grade. The permanent activation of the EGFR/PI3K/AKT pathway by various genetic or post-translational alterations of EGFR, PI3KCA, and PTEN has been associated with increased proliferation and resistance to apoptosis. The present study aimed to analyze the molecular/genetic changes in the EGFR/PI3K/AKT/PTEN pathway between low-grade and high-grade gliomas in a sample of Colombian patients. A total of 30 samples were tested for PI3K and PTEN mutations, EGFR, PI3K, and AKT gene amplification, AKT, PI3K, BAX, Bcl2 expression levels, and phosphorylation of AKT and PTEN, EGFR and/or PI3K gene amplification was found in 50% of low-grade and 45% of high-grade ones. AKT amplification was found in 25% of the low-grade and 13.6% of the high-grade. The expression of PI3K, AKT, Bcl2, and BAX was increased particularly to a high degree. AKT phosphorylation was found in 66% of low-grade and 31.8% of high-grade. Increased phosphorylation of PTEN was found in 77% low-grade and 66% high-grade. Our results indicate that alterations in the EGFR/PI3K/AKT/PTEN pathway could be important in the initiation and malignant progression of this type of tumor.

show abstract

Section: Discussionsupporting

confidence: 89%

Differential Regulation of the EGFR/PI3K/AKT/PTEN Pathway between Low- and High-Grade Gliomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We further checked the effects of ABT199, a Bcl-2 inhibitor, and ABT263, a Bcl-1/Bcl-X L /Bcl-w inhibitor [ 7 , 25 ], on the growth of this panel of CRC cell lines. In general, both inhibitors, particularly ABT263, generated similar cell response patterns to APG-1252-M1 (Fig.…”

Section: Resultsmentioning

confidence: 99%

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

et al. 2022

View full text Add to dashboard Cite

“…Bcl‐2 is a key regulator of mitochondrial outer membrane permeabilization, the most important aspect of intrinsic apoptosis (Singh et al, 2019). Since apoptosis deficiency is a common feature observed in neoplastic diseases, targeting Bcl‐2 has been an emerging strategy in cancer therapeutics (Oltersdorf et al, 2005; Zhang et al, 2021). The significance of Bcl‐2 in melanocytic lineage survival was clearly illustrated by the observation that Bcl‐2 deletion causes dramatic melanocyte loss in mice (Nishimura et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Establishment and characterization of an immortalized human giant congenital melanocytic nevi cell line

Aimaier

Chung

et al. 2022

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Congenital melanocytic nevi are benign melanocytic tumors that are present at birth. When the diameter of the nevus reaches 20 cm in projected adult size, it is known as a giant congenital melanocytic nevus (GCMN) (Alikhan et al., 2012;Tannous et al., 2005). The estimated incidence of GCMN is between 1/50,000 and 1/20,000 births. GCMN could involve any area of the body surface, and the pigmented appearance presents a heavy psychological burden to the patients and their families. Simultaneously, GCMN has a high risk of transformation into malignant melanomas, as compared with smaller-sized nevi. It is estimated that 5%-10% of patients with GCMN are at risk of developing malignant melanoma (Price &

show abstract

Targeting Bcl-2 for cancer therapy

Cited by 64 publications

References 237 publications

Differential Regulation of the EGFR/PI3K/AKT/PTEN Pathway between Low- and High-Grade Gliomas

Differential Regulation of the EGFR/PI3K/AKT/PTEN Pathway between Low- and High-Grade Gliomas

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

Establishment and characterization of an immortalized human giant congenital melanocytic nevi cell line

Contact Info

Product

Resources

About